Is the TB protein ESAT-6 helpful for vaccines?
A novel approach to determine the value of ESAT-6 as an antigen in M. tuberculosis infection and vaccines
Researchers are looking at whether the tuberculosis protein ESAT-6 helps the immune system fight TB to guide better vaccines for people at risk.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11267237 on NIH RePORTER |
What this research studies
You should know that this project focuses on ESAT-6, a protein from the TB bacterium that triggers strong immune responses. The team will compare immune responses to vaccines that include ESAT-6 versus those that do not using laboratory assays and animal models. They will measure T cell and antibody responses and how well those responses protect against TB infection. The goal is to find out if ESAT-6 improves protection or acts as a distracting 'decoy' that reduces vaccine effectiveness.
Who could benefit from this research
Good fit: This research would most directly interest people at risk of TB, those with prior BCG vaccination, or people who might join future TB vaccine trials.
Not a fit: People currently being treated for active TB are unlikely to receive direct benefit from this laboratory-focused work.
Why it matters
Potential benefit: If successful, this work could clarify whether ESAT-6 should be included or avoided in TB vaccines, helping researchers design more effective vaccines that reduce TB risk.
How similar studies have performed: Previous vaccine efforts that included ESAT-6 have produced only modest protection in animals and mixed results in humans, so the role of ESAT-6 remains unclear.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Ernst, Joel D. — University of California, San Francisco
- Study coordinator: Ernst, Joel D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.